Mitochondrial apoptosis is controlled by proteins of the B-cell lymphoma 2 (Bcl-2) family. Pro-apoptotic members of this family, known as BH3-only proteins, initiate activation of the effectors Bcl-2-associated X protein (Bax) and Bcl-2 homologous antagonist/ killer (Bak), which is counteracted by anti-apoptotic family members. How the interactions of Bcl-2 proteins regulate cell death is still not entirely clear. Here, we show that in the absence of extrinsic apoptotic stimuli Bak activates without detectable contribution from BH3-only proteins, and cell survival depends on anti-apoptotic Bcl-2 molecules. All anti-apoptotic Bcl-2 proteins were targeted via RNA interference alone or in combinations of two in primary human fibroblasts. Simultaneous targeting of B-cell lymphoma-extra large and myeloid cell leukemia sequence 1 led to apoptosis in several cell types. Apoptosis depended on Bak whereas Bax was dispensable. Activator BH3-only proteins were not required for apoptosis induction as apoptosis was unaltered in the absence of all BH3-only proteins known to activate Bax or Bak directly, Bcl-2-interacting mediator of cell death, BH3-interacting domain death agonist and p53-upregulated modulator of apoptosis. These findings argue for auto-activation of Bak in the absence of anti-apoptotic Bcl-2 proteins and provide evidence of profound differences in the activation of Bax and Bak. Cell Death and Disease (2015) 6, e1996; doi:10.1038/cddis.2015.341; published online 26 November 2015
Bcl-2 proteins with varying preferences. 4 As this may neutralize a combination of anti-apoptotic proteins it may facilitate Bax/Bak activation by activator BH3-only proteins. Consequently, this group of BH3-only proteins has been named 'sensitizer' or 'derepressor' BH3-only proteins. 3, [5] [6] [7] The direct activation model has received recent support by structural studies of activator BH3-domains bound to Bax. 8 That study also found that the BH3-only peptides used previously lacked a residue that is important in the activation of Bax, and the previous results may have to be reconsidered. Indeed, a recent study illustrates that placing the BH3-domain from the various BH3-only proteins into intact Bid protein enhances Bax/Bak-activating capacity of the BH3-domains of Bid, Bim, Puma, Bmf (Bcl-2-modifying factor), Bik and Hrk. 9 The displacement (or indirect activation) model on the other hand posits that Bax and Bak are held in check by anti-apoptotic Bcl-2 proteins and auto-activate when this interaction is broken by BH3-only proteins (displacement). BH3-only proteins can bind to anti-apoptotic Bcl-2 proteins and upon apoptotic stimulation may cause the displacement of these proteins from Bax and Bak, which may lead to the activation of effectors. BH3-peptides derived from Bim and Puma can bind to all anti-apoptotic Bcl-2 proteins and its corresponding proteins exert killing upon overexpression, whereas Bad, Bmf, Bid, Bik, Hrk and Noxa display binding patterns restricted to certain anti-apoptotic Bcl-2 proteins. 4 It was therefore suggested that Bax/Bak activation requires the neutralization/displacement of several anti-apoptotic proteins, which may be achieved by one BH3-only protein with broadly binding characteristics (such as Bim) or by the combination of BH3-only proteins with restricted binding capabilities (for instance Bad plus Noxa). 10, 11 The models have been further refined; the 'embedded together' model additionally considers the dynamic interaction of the proteins with the mitochondrial membrane, 12 and it has been proposed that the models can be unified by taking two 'modes' of inhibition into account: anti-apoptotic Bcl-2 proteins have a dual function in inactivating both, BH3-only proteins and effectors. Pro-apoptotic signals cause the release of activator BH3-only proteins from sequestration with antiapoptotic Bcl-2 proteins. Free BH3-only proteins directly activate effectors, however, cell death may still not be initiated because the effectors are then held in check by anti-apoptotic Bcl-2 proteins. Free activator BH3-only proteins are required to activate effectors. 13 This model unifies the two above models in the sense that it incorporates aspects of both, inhibition and displacement as well as direct activation. However, the core difference between the (direct) activation and the displacement model appears to be irreconcilable: in the activation model Bax and Bak are inactive unless receiving a stimulus from BH3-only proteins whereas in the displacement model they are active unless bound to anti-apoptotic proteins. Thus, in the absence of all other proteins one model predicts that Bax/Bak are active, the other that they are inactive. Obviously they cannot be both.
The direct activation model has initially been established with Bax and the displacement model with Bak. The data are very strong that Bax is activated by direct interaction with BH3-only proteins. Recombinant Bak can also be directly activated by recombinant tBid, 14 and Bid/BH3-chimaeras can activate recombinant Bak missing its C terminus. 9 However, since Bak is normally inserted into the outer mitochondrial membrane where it may be bound to numerous other Bcl-2-family members, it has been difficult directly to test activation of Bak in the physiological situation.
One possibility to 'unify' the original models may be in a model where Bax is physiologically activated by direct activation (Bax is inactive until receiving a signal through BH3-only proteins) whereas Bak is activated indirectly (auto-activates when the inhibition by Bcl-2-like proteins is relieved). Here we test this possibility of indirect Bak activation. We targeted anti-apoptotic Bcl-2 family proteins using RNAi. In this setting, protein concentrations and conditions are physiological, which avoids some of the problems associated with overexpression or cell-free experiments. Non-malignant cells may respond differently to the loss of anti-apoptotic Bcl-2 proteins compared with tumor cells. 15 In this study, using nonmalignant cells, we targeted all anti-apoptotic Bcl-2 molecules in combinations of two. In the absence of apoptotic stimuli we observed that the combined loss of Bcl-X L and Mcl-1 was sufficient to induce apoptosis. The direct activator proteins Bid, Bim and Puma were not needed. These observations provide evidence for indirect activation of Bak.
Results
Combined targeting of Bcl-X L and Mcl-1 induces apoptosis in primary human cells. We recently investigated anti-apoptotic Bcl-2 proteins to evaluate a strategy to induce apoptosis in a tumor-specific way and observed that -in contrast to tumor cells -targeting of a single anti-apoptotic Bcl-2 protein by RNAi does not affect survival of primary (non-transformed) human fibroblasts. 15 To understand whether any anti-apoptotic proteins are required for survival we analysed the effect of combined simultaneous RNAi to two anti-apoptotic Bcl-2 proteins. All combinations of two of the anti-apoptotic Bcl-2 proteins, Bcl-2, Bcl-X L , Bcl-w, Mcl-1 and A1 were tested and efficient targeting of all proteins was achieved ( Figure 1a and ref. 15 for A1). Although most combinations did not lead to significant cell death, targeting of Bcl-X L and Mcl-1 killed~60% of cells within 3 days (Figure 1b ; a less complete study in HeLa cells has also reported that simultaneous targeting of Bcl-X L and Mcl-1 induces apoptosis 16 ). To a lesser extent, targeting of Bcl-X L and Bcl-w caused cell death, however, induction of Noxa was observed there (data not shown). Noxa inactivates Mcl-1, and experimental expression of Noxa sensitized the cells to RNAi against Bcl-X L alone (see below). Cell death upon targeting of Bcl-X L /Bcl-w may therefore not be due to the loss of Bcl-2-function but the Noxa-mediated inactivation of Mcl-1, together with RNAi against Bcl-X L ; this targeting may thus have the same molecular effect as RNAi against the combination of Bcl-X L and Mcl-1. Therefore, the relevance of Bcl-X L /Bcl-w for cell death cannot be addressed in this approach. Activation of caspase-9 and caspase-3 was observed by western blotting (Figure 1c) . Cleavage of caspase-8 was also observed, which very likely was subsequent to the activation of effector caspases. To confirm this finding in another setting, we ectopically expressed Noxa along with siRNA-mediated targeting of Bcl-2, Bcl-X L and Bcl-w. Only upon targeting of Bcl-X L , Noxa expression led to apoptosis. As Noxa specifically targets Mcl-1 this is additional evidence that specifically Mcl-1 inactivation along with Bcl-X L targeting leads to cell death (Figure 1d ). Finally, we tested this combination in different cell types and compared primary human fibroblasts (mesenchymal cells) with primary human keratinocytes (epithelial cells) and immortalized human microvascular endothelial cells.
Targeting of Bcl-X L and Mcl-1 caused cell death also in these cell types (Figure 1e ). These data show that specifically the combined loss of Bcl-X L and Mcl-1 induces cell death in a number of different primary cells without further stimulus. ( Figure 2a) . Surprisingly, targeting of Bak almost completely blocked cell death, whereas targeting of Bax had no significant effect on cell death (Figure 2b ). We also measured the proportion of cells with activated Bax, using staining for the 6A7 epitope in active Bax. Bax was found to be activated upon targeting of Bcl-X L /Mcl-1 ( Figure 2c ). However, no activation was seen when Bak had been targeted at the same time, suggesting that Bax activation is secondary to Bak activation but Bax cannot be activated in its absence ( Figure 2c ).
Apoptosis upon targeting of Bcl-X L and Mcl-1 in murine embryonic fibroblasts depends on Bak. To confirm Bak dependency of apoptosis induced by the loss of Bcl-X L /Mcl-1, we used murine embryonic fibroblasts (MEFs) WT or deficient for Bak, Bax or double deficient for both. Knock-down of Mcl-1 and Bcl-X L was also efficient in these cells (Figure 3a ). Similar to human fibroblasts, targeting of Bcl-X L /Mcl-1-induced apoptosis in WT-MEFs, which was not observed in Bax/Bak-DKO-MEFs (Figure 3b ). Whereas apoptosis in Bax-deficient MEFs was similar to the levels in WT-MEFs, it was substantially reduced in Bak-deficient MEFs (Figure 3c ). There was a very small pro-apoptotic effect also in Bak-deficient cells ( Figure 3C ). This may be a BH3-only protein-dependent effect (for instance, the targeting of the anti-apoptotic proteins may release some Bim), or it may be that in the absence of Bcl-X L , which can retro-translocate Bax from mitochondria to the cytosol, 17 the accumulation of Bax at mitochondria will have a small pro-apoptotic effect. The effect was however minuscule compared to the effect of Bak (suggested by the effect in Bax-versus Bak-deficient cell, Figure 3c ).
We also tested Mcl-1-deficient MEFs. Here, targeting of Bcl-X L was sufficient to induce cell death and again, cell death was dependent on Bak, but not on Bax (Figure 3d ). Together, these results confirm the findings in murine embryonic fibroblasts in different settings of Bcl-2 protein family deficiency. This could be due either to the liberation of Bak from these two anti-apoptotic molecules or to the direct activation of Bak by BH3-only proteins, which may either be released from Bcl-X L /Mcl-1 or increased in expression. First, we tested expression levels of BH3-only proteins with known capacity to directly activate effector Bcl-2 proteins, namely Bim, Bid and Puma. Bim-mRNA was not altered upon targeting of Bcl-X L /Mcl-1 whereas protein levels were surprisingly reduced ( Figure 4a ). Bid mRNA was not altered; however, a slight reduction of Bid protein levels was observed, whereas tBid was not detectable (Figure 4b ). It cannot fully be excluded that reduced Bid levels represent Bid activation even in the absence of detectable tBid. We therefore tested whether Bid levels were also reduced in the absence of Bak. Bid levels were not found to be reduced upon targeting of Bak Together, the data suggest that most BH3-only proteins are not induced. Some BH3-only proteins were induced in a Bak-dependent way, suggesting that this induction is downstream of Bak. Therefore expression changes of these molecules very likely do not function as a trigger for apoptosis initiation.
Individual BH3-only proteins are not required for apoptosis induction upon loss of Bcl-X L /Mcl-1. To examine the relevance of BH3-only proteins more rigorously, we tested whether knock-down of BH3-only proteins affected apoptosis upon targeting of Bcl-X L /Mcl-1. We silenced Bim, Bid, Bad or Puma by RNAi in human fibroblasts. siRNA treatment strongly reduced the mRNA levels of the targeted gene (Figure 5a ). However, induction of apoptosis was not affected when any of these molecules were targeted along with Bcl-X L /Mcl-1 (Figure 5b ). The studies were also extended to Mcl-1-deficient MEFs, where two BH3-only proteins, described to directly activate Bax or Bak, were targeted simultaneously. No alteration of apoptosis induction was observed (Figure 5c and d) .
These data suggest that individual BH3-only proteins are not required for apoptosis induced by loss of Bcl-X L and Mcl-1, further providing evidence that removal of Bcl-X L and Mcl-1 is sufficient to induce cell death.
Apoptosis induced by Bcl-X L /Mcl-1 inhibition occurs in absence of activator BH3-only proteins. We next tested whether the combined inhibition of known activator BH3-only proteins may affect cell death. We used Mcl-1-deficient MEFs and successfully silenced Bim, Bid and Puma (Figure 6a ). Even simultaneous knock-down of these molecules did not affect apoptosis induction (Figure 6b The induction of apoptosis was confirmed by annexin V-positive/propidium staining and by demonstrating the activation of caspase-3 ( Figure 6f ). To rule out that any activator BH3-only molecule is relevant for apoptosis upon Bcl-X L /Mcl-1 loss, we generated MEFs that are triple deficient for Bim, Puma and Bid. For this, CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/endonuclease) was used to generate Bid-deficient cells on the basis of Bim/Puma-knockout MEFs cells. Triple-knockout cells still strongly underwent apoptosis when Bcl-X L /Mcl-1 were targeted using different siRNA sequences (Figure 6g ). To further exclude the involvement of BH3-only proteins we took advantage of a third experimental model and prepared mitochondria from human fibroblasts treated with Bcl-X L -, Mcl-1-, and Bak-specific siRNA. These cells survive due to the lack of Bak (Figure 2a) . If BH3-only proteins were activated in these cells, they would be localized at the membrane of the isolated mitochondria and would be able to activate exogenously added Bax, leading to release of cytochrome c. When active Bim is overexpressed in Bax/Bak double-deficient mitochondria, low levels (about 50 nM) of recombinant Bax are sufficient to cause cytochrome c release. 18 In mitochondria from Bax/Bak double-deficient MEFs that had not been manipulated, high levels (1000 nM) of recombinant Bax caused release of cytochrome c (Figure 6h ). However, even at this high concentration Bax did not lead to release of cytochrome c from mitochondria isolated from human fibroblasts treated with siRNAs targeting Bcl-X L , Mcl-1, and Bak (Figure 6i ). This indicates that there is no active BH3-only protein at the mitochondria that may have led to Bak activation, when cells have lost Bcl-X L and Mcl-1.
Together these data demonstrate that even the loss of all activator BH3-only proteins does not affect apoptosis induced by inhibition of Bcl-X L and Mcl-1. Further, this occurs in the absence of active BH3-only proteins at mitochondria. This strongly suggests that BH3-only proteins are not involved in apoptosis initiation upon loss of Bcl-X L and Mcl-1 in these cells.
Discussion
Our results show that the removal of two anti-apoptotic proteins in several non-malignant cell types activates Bak and subsequently causes apoptosis, which appeared not to require BH3-only proteins. This suggests that Bak indeed can auto-activate when this inhibition is removed. These results may provide an explanation why cells express both Bax and Bak despite their apparent biological redundancy.
Arguably, the activation of Bax is better understood than the activation of Bak. Bax can be directly bound by BH3-domains of Bim and Bid. 8 Bax is normally inactive in the cytosol but very likely can be activated by direct interaction with the BH3-domain of BH3-only proteins. BH3-only proteins (with the exception of Bad) are tail-anchored in the outer mitochondrial membrane. 7, 18 It seems a likely model that Bax can be activated by BH3-only proteins as it diffuses past the mitochondrial membrane, where it inserts and triggers the release of cytochrome c.
It may however not be appropriate to assume the same for Bak. Bak is in the absence of apoptosis already inserted in the OMM. Although Bak can in principle be activated by BH3-only proteins and this may occur through direct binding, the requirements for the activation of Bax versus Bak, with their different spatial constraints, are likely different. Further, Bak can bind Bcl-X L and Mcl-1 in principle, 10 and all three proteins are at mitochondria; it therefore appears likely that there is some binding in a normal, non-apoptotic cell.
Conversely, the indirect activation model is counter-intuitive for Bax, with its primarily cytosolic localization: although the potential binding to anti-apoptotic Bcl-2-proteins for Bax may be suggestive, 11 Bax is clearly at least predominantly cytosolic. Accordingly, the studies of 'displacement' have experimentally focused on Bak and have extrapolated the findings to Bax. There is clear evidence that the activation of Bax can involve a measure of displacement, or indirect activation. This however is seen in situations where apoptosis had been initiated but then blocked by anti-apoptotic Bcl-2 proteins. As elaborated on by the 'unified model' the inhibition of active Bax and Bak is an important function of Bcl-2-like proteins.
Indeed, this way of activation of Bax may be an important difference between tumor cells and non-malignant cells. In many cases tumor development creates the need for alterations that help transformed cells escape defense mechanisms of the host organism such as apoptosis. 19 We have observed previously that a cell lineage-specific expression profile of antiapoptotic Bcl-2 proteins is lost in tumor cells, which is associated with increased dependency of tumor cells on these proteins. 15 Compared with cancer cells, the studies investigating anti-apoptotic Bcl-2 members in non-malignant cell are less comprehensive.
In a study of cancer cells, where a small molecule library was used to identify compounds inhibiting Mcl-1, Bcl-X L was identified as the only marker predicting sensitivity to Mcl-1-inhibiting compounds, and these small molecules induced apoptosis via Bak not Bax. 20 In the non-transformed cells we used here only the simultaneous removal of Bcl-X L and Mcl-1 but not either on its own (or in combination with any other Bcl-2-like protein) induced apoptosis. We observed this in several non-malignant cell types, indicating a more common survival regulation. This difference between cancer cells and normal cells may be interpreted as an indication of a pre-activated Bcl-2-system in tumor cells. In other cell types this dependency may be different again. Mcl-1 is critically required for the development and maintenance of many cells of the hematopoietic system and it is sufficient to take away Mcl-1 in mature lymphocytes to induce apoptosis. 21 Together, our study provides evidence that Bak may be activated independently of BH3-only proteins in non-malignant cells. It therefore appears that Bak may auto-activate, and this may be the main mechanism of its activation. Bax and Bak can in many situations have the same activity and replace each other, and there seems no plausible explanation why we have two effector proteins that act exactly the same way. A different mode of activation with Bax requiring activation through BH3-only proteins and Bak auto-activating when the inhibition is removed would appear to provide a reason for the presence of both.
Materials and Methods
Reagents and antibodies. Anti-Bcl-2 (Ab-1) antibody was purchased from Merck Biosciences (Darmstadt, Germany). Anti-Bcl-X L , anti-Bcl-w, anti-Bid, anti-Bim (C34C5), anti-Bak, anti-caspase-3, anti-caspase-8 (1C12), anti-caspase-9 and HRPconjugated secondary antibodies were obtained from New England Biolabs (Berlin, Germany). Anti-Mcl-1 (22) antibody was from BD Bioscience (Heidelberg, Germany), anti-Bax (2D2) was from Santa Cruz Biotechnology (Heidelberg, Germany) and anticytochrome c (clone 7H8.2C12) was purchased from BD Biosciences (Heidelberg, Germany). Anti-β-actin (AC-15) and anti-α-tubulin (DM1A) antibodies were obtained from Sigma-Aldrich (Munich, Germany). Bax activation was measured via flow cytometry by staining with an antibody specific for the conformation of activated Bax (Clone 3; BD Pharmingen, Heidelberg, Germany). PCR primers and siRNAs were purchased from Eurofins MWG Operon (Ebersberg, Germany).
siRNAs. siRNAs were designed as described previously. 22 Sequences of specific siRNAs were A1 (human): GGAAGAAUUGUAACCAUAU, Bad (human): GGATGAGTGACGAGTTTGT, Bak (human): GCTTCGTGGTCGACTTCAT, Bak Generation of Bim, Puma, Bid triple knockout MEF using CRISPR/Cas9. Bid was specifically targeted in Bim/Puma double-deficient MEF by using a two vector based CRISPR/CAS9 system kindly provided by Dr. Veit Hornung (Institute of Molecular Medicine, University Hospital Bonn, Germany) by transient transfection and subsequent selection. Efficacy was tested using antibody against Bid.
Cell culture. Primary human fibroblasts and keratinocytes were isolated from neonatal human foreskins. Cultivation of cells was described previously. 23 Human microvascular endothelial cells and immortalized murine embryonal fibroblasts (MEFs) were cultivated in DMEM (Dulbecco's modified Eagle's medium) medium supplemented with 10% FCS (fetal calf serum).
Transfection procedures. siRNA transfections were performed in 6-well dishes in a volume of 1 ml utilizing Lipofectamine RNAiMAX (Invitrogen, Darmstadt, Germany) according to the manufacturer's protocol. For inhibition of a single gene, 20 nM siRNA together with 1.25 μl Lipofectamine RNAiMAX was used. For dual or triple inhibition experiments, each specific siRNA was used in a concentration of 20 nM. The amount of control siRNA was adjusted to the total amount of specific siRNAs used in the experiment as indicated in the figures. In dual inhibition experiments 40 nM specific siRNAs or 40 nM control siRNA, in triple inhibition experiments 60 nM siRNAs or 60 nM control siRNA was used together with 2 μl Lipofectamine RNAiMAX. Plasmides were transfected at 1 μg/ml with 3 μl FuGENE 6 (Roche) according to the manufacturer's protocol.
Quantification of viable cells. Viable cells with intact metabolism were identified by their ability to reduce cell-permeable resazurin to fluorescent resorufin. Medium was replaced with 750 μl of culture medium and 150 μl of CellTiter-Blue reagent (CellTiter-Blue Cell Viability Assay; Promega, Mannheim, Germany). After 1 h incubation at 37°C, fluorescence was measured.
Quantification of apoptotic cells and cell death. Adherent and supernatant cells were analyzed by staining with FITC-labeled Annexin V (Roche, Mannheim, Germany) and propidium iodide (Sigma-Aldrich) as described previously. 24 Cells were analyzed by fluorescence-activated cell sorting analysis using CellQuest software (BD Bioscience).
RNA extraction and quantification. Total RNA was extracted from cells using QIAzol Lysis Reagent (Qiagen, Hilden, Germany) as described by the manufacturer and analyzed by quantitative RT-PCR. Reverse transcription and quantification procedures using the LightCycler TaqMan Master Kit (Roche) together with the Universal Probe Library system (Roche) were described previously. 24 Relative gene expression was expressed as a ratio of the expression level of the gene of interest to that of hypoxanthine phosphoribosyltransferase RNA determined in the same sample.
Protein preparation and immunoblot analysis. Adherent and supernatant cells were lysed in buffer containing 50 mM Tris, pH 7.4, 0.25 M NaCl, 1 mM EDTA, 0.1% Triton X-100, phosphatase inhibitors (PhosSTOP, Roche) and protease inhibitors (Complete, Mini, EDTA-free; Roche). Gel electrophoresis, blotting and protein detection was carried out using the Xcell SureLock Mini-Cell apparatus (Invitrogen) as described previously. 24 Protein levels of β-actin or α-tubulin were analyzed as a control for constant loading and transfer.
Isolation and treatment of mitochondria. Mitochondria were isolated with a cell homogenizer (Isobiotec, Germany) pre-cooled on ice together with a 10 mm tungsten carbide ball inserted. The homogenizer was equilibrated with isolation buffer (PBS supplemented with protease inhibitor cocktail for mammalian cell (Sigma-Aldrich)). A total of 5 × 10 6 cells were resuspended in 1 ml of isolation buffer and cell membranes were ruptured by passing the cell suspension three times through the system. The homogenate was recovered by rinsing once with 1 ml of isolation buffer and centrifuged (800 × g, 5 min at 4°C) to remove cell debris and nuclei. The supernatant was centrifuged at 9000 × g (10 min at 4°C) and the mitochondria-containing pellet was resuspended in 50 μl of isolation buffer. A total of 30 μg of the mitochondrial sample were centrifuged (9000 × g, 10 min at 4°C) and resuspended in 20 μl of KCl buffer (10 mM HEPES pH 7.4, 125 mM KCl, 4 mM MgCl 2 , 5 mM KH 2 PO 4 and 0.5 mM EGTA), supplemented with Bax as indicated in respective experimental conditions. Mitochondria were incubated for 30 min at 30°C and mitochondria were pelleted at 9000 × g for 10 min at 4°C. Supernatant was collected and pelleted mitochondria were washed in 150 μl KCl buffer and resuspended in 20 μl of KCl buffer. Supernatant and mitochondrial fractions were analyzed by immunoblotting.
Statistics. For statistical analysis, two-tailed Student's t-test was used to assess the significance of mean differences. Differences were considered significant at a P-value of 0.05 or less (indicated in the Figures (n.s. , not significant; P40.05)).
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